Bioidentical hormones
- PMID: 33403887
- DOI: 10.1080/13697137.2020.1862079
Bioidentical hormones
Abstract
After the results of the Women's Health Initiative trials were published, patient and clinician interest in potential alternatives to conventional hormone therapy (HT) has grown. A commonly used alternative therapy involves custom-compounded steroid hormone preparations, formulated by compounding pharmacies. Many postmenopausal women consider the hormones as natural or bioidentical, in contrast to hormones used in conventional HT, which they consider synthetic. In actuality, the chemical structures of many of the hormones used in bioidentical HT (BHT) are the same as those used in conventional HT. To customize formulations, compounding pharmacies frequently use saliva testing to measure hormones. However, there is a misconception that salivary hormone levels are equivalent to non-protein-bound (free) hormones in blood. Because hormonal custom-compounded formulations are not approved by the Food and Drug Administration (FDA), there are concerns regarding their purity, potency, and quality. Evolving regulatory guidelines by the FDA on oversight of these products should lessen the concerns regarding their safety and efficacy. This review addresses important misconceptions and uncertainties pertaining to BHT, the relationship between salivary and serum/plasma steroid hormone concentrations, the effect of topical progesterone creams on the endometrium, the variability in custom-compounded steroid preparations, and FDA oversight of custom-compounded products.
Keywords: Bioidentical; compounding; estrogens; postmenopause; progesterone; salivary testing.
Similar articles
-
Bioidentical hormone therapy: a review of the evidence.J Womens Health (Larchmt). 2007 Jun;16(5):600-31. doi: 10.1089/jwh.2006.0311. J Womens Health (Larchmt). 2007. PMID: 17627398 Review.
-
What are the concerns about custom-compounded "bioidentical" hormone therapy?Menopause. 2014 Dec;21(12):1298-300. doi: 10.1097/GME.0000000000000376. Menopause. 2014. PMID: 25387347
-
Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6.Obstet Gynecol. 2023 Nov 1;142(5):1266-1273. doi: 10.1097/AOG.0000000000005395. Obstet Gynecol. 2023. PMID: 37856860
-
Spotlight on Compounded Bioidentical Hormones.Gynecol Obstet Invest. 2024;89(1):31-40. doi: 10.1159/000535982. Epub 2023 Dec 27. Gynecol Obstet Invest. 2024. PMID: 38151014 Review.
-
Compounded bioidentical hormone therapy: new recommendations from the 2020 National Academies of Sciences, Engineering, and Medicine.Menopause. 2021 Mar 11;28(5):576-578. doi: 10.1097/GME.0000000000001735. Menopause. 2021. PMID: 33739316
Cited by
-
Evaluation of an Anhydrous Permeation-Enhancing Vehicle for Percutaneous Absorption of Hormones.AAPS PharmSciTech. 2022 Jul 19;23(6):198. doi: 10.1208/s12249-022-02352-3. AAPS PharmSciTech. 2022. PMID: 35854200
-
Management of menopausal hot flushes. Recommendations from the Spanish Menopause Society.Eur J Obstet Gynecol Reprod Biol X. 2025 Jan 23;25:100366. doi: 10.1016/j.eurox.2025.100366. eCollection 2025 Mar. Eur J Obstet Gynecol Reprod Biol X. 2025. PMID: 39944633 Free PMC article. Review.
-
Position paper of the expert panel of the Polish Society of Menopause and Andropause on the use of Oestrogel® in menopausal hormone therapy.Prz Menopauzalny. 2025 Jun;24(2):131-136. doi: 10.5114/pm.2025.152241. Epub 2025 Jun 23. Prz Menopauzalny. 2025. PMID: 40777875 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical